On this page
- TL;DR
- Testicular cancer VA rating criteria (DC 7528)
- Testicle removal (orchiectomy), atrophy and SMC(k)
- Is testicular cancer presumptive? PACT Act and the one-year rule
- How to prove testicular cancer is service connected
- Testicular cancer treatment residuals to document
- The testicular cancer C&P exam
- Why VA denies testicular cancer claims
- Questions veterans ask about testicular cancer
- Bottom Line
- Sources and limits
Active testicular cancer is evaluated under Diagnostic Code 7528 for malignant neoplasms of the genitourinary system. The current schedule assigns 100 percent while the malignancy is active and during surgical, radiation, chemotherapy, or other antineoplastic treatment. The 100-percent evaluation continues after treatment ends until VA conducts the mandatory examination required six months later.
If there has been no local recurrence or metastasis, VA then rates the remaining disability as voiding dysfunction or renal dysfunction, whichever predominates. Removal or atrophy of a testis may also fall under DC 7524 or 7523, and the schedule directs VA to review possible special monthly compensation.
This page covers the testicular cancer rating criteria, testicle removal and SMC(k), the PACT Act and one-year presumptions, how to prove service connection, the treatment residuals to document, the C&P exam, and why VA denies testicular cancer claims.
TL;DR
- Active testicular cancer and antineoplastic treatment rate at 100 percent under DC 7528.
- The 100-percent evaluation continues after treatment ends, with a mandatory VA examination at six months.
- If there is no recurrence or metastasis, DC 7528 directs VA to rate the predominant voiding or renal residual.
- Removal of one testis is 0 percent under DC 7524; removal of both is 30 percent, subject to the code's special note.
- Anatomical loss of a testis should trigger review for SMC-K, but the applicable facts and service connection still must be established.
- Testicular cancer may be presumptive as a reproductive cancer for qualifying toxic-exposure service under the PACT Act. It is not on the Agent Orange presumptive list.
- Malignant tumors are also listed chronic diseases, so manifestation to a compensable degree within one year after qualifying service may support a presumption.
- Fertility, endocrine, neurologic, scar, and other treatment effects should be documented even when they are not the residual route named in DC 7528.
- Across 245 decided Board rulings on testicular cancer from 2021 to 2026, 26.9% were granted, 30.2% denied and 42.9% remanded.
Testicular cancer VA rating criteria (DC 7528)
38 CFR § 4.115b assigns 100 percent for a malignant neoplasm of the genitourinary system. The note to DC 7528 keeps that evaluation in place after surgical, radiation, chemotherapy, or other treatment ends. VA then schedules an examination six months after cessation of treatment. The DC 7528 reference shows the schedule alongside this guide.
The examination is a decision point, not an automatic reduction date. If the cancer has recurred locally or metastasized, the 100-percent evaluation continues. If it has not, the code directs rating based on voiding dysfunction or renal dysfunction, whichever is predominant. Any reduction must also follow the notice protections in § 3.105(e) when they apply: VA has to propose the reduction, explain why, and give you 60 days to send evidence before it takes effect.
Treatment records should identify the date active treatment actually ended. Surveillance, laboratory monitoring, and follow-up imaging do not necessarily equal antineoplastic treatment. The oncologist's characterization of the treatment course matters.
Testicle removal (orchiectomy), atrophy and SMC(k)
When a testis has been removed, DC 7524 provides these ratings.
- 0 percent for removal of one testis; and
- 30 percent for removal of both testes.
The code has a special note. If one testis was removed because of a service-incurred injury or disease, and the other testis is absent or nonfunctioning for reasons unrelated to service, VA assigns 30 percent for the service-connected loss. An undescended or congenitally undeveloped testis is not a ratable disability. Compare the actual facts with that note rather than assuming the ordinary one-testis percentage resolves the claim.
DC 7523 rates complete atrophy of one testis at 0 percent and both at 20 percent. Both codes direct adjudicators to review entitlement under 38 CFR § 3.350. Anatomical loss of a creative organ may support SMC-K even when the schedular orchiectomy percentage is 0. Section 3.350(a) says loss of a creative organ is shown by the acquired absence of one or both testicles (other than undescended testicles). Loss from an elective operation after service does not count, but an operation advised on sound medical judgment to treat a disease, such as an orchiectomy for cancer, is not treated as elective. The current payment amount should be checked on VA's compensation-rate page rather than hard-coded into a condition guide.
Is testicular cancer presumptive? PACT Act and the one-year rule
VA's PACT Act benefits guide includes reproductive cancer of any type among covered presumptive cancers for veterans with qualifying service and exposure. The statute, 38 U.S.C. § 1120, lists "reproductive cancer of any type." Testicular cancer falls within that reproductive-cancer category, but the veteran must still meet the service-location requirements in 38 U.S.C. § 1119(c). Those cover service on or after August 2, 1990 at a duty station in Bahrain, Iraq, Kuwait, Oman, Qatar, Saudi Arabia, Somalia or the United Arab Emirates, and service on or after September 11, 2001 in Afghanistan, Djibouti, Egypt, Jordan, Lebanon, Syria, Yemen, Uzbekistan, or another country VA adds, including the airspace above each.
The PACT route is not the only possible presumption. 38 CFR § 3.309(a) lists malignant tumors as chronic diseases. Under § 3.307, manifestation to at least a 10-percent degree within one year after qualifying separation may support presumptive service connection even if the formal diagnosis came later. That presumption generally needs 90 days or more of service during a war period or after December 31, 1946. A retrospective oncology opinion can be important when symptoms or a mass were present during that window but the workup finished afterward.
Testicular cancer is not on the Agent Orange list in § 3.309(e). A Vietnam-era claim for it needs the one-year rule, the PACT Act route if the veteran also has covered later service, or direct evidence.
How to prove testicular cancer is service connected
Direct service connection under § 3.303 may apply when the cancer began in service or a clinician connects it to an in-service event or exposure. Useful evidence can include the following.
- service records documenting a mass, swelling, pain, imaging, tumor markers, or referral;
- pathology identifying the malignancy and histologic type;
- operative, oncology, chemotherapy, and radiation records;
- a timeline from first symptoms to diagnosis; and
- a medical opinion addressing onset or a documented exposure when no presumption applies.
A diagnosis after service does not by itself prove or disprove onset during service. Section 3.303(d) allows service connection for a disease first diagnosed after discharge when all the evidence shows it was incurred in service. The medical opinion should discuss the tumor's course and the actual record rather than rely only on the date pathology was signed.
Testicular cancer treatment residuals to document
A 2025 JAMA review describes treatment that starts with a radical inguinal orchiectomy and, depending on tumor type and stage, may include surveillance, retroperitoneal lymph-node surgery, chemotherapy, or radiation. A 2024 review of late effects in survivors lists hypogonadism, infertility, peripheral neuropathy, hearing loss, reduced kidney function, cardiovascular disease and anxiety, among others. The resulting record may raise issues beyond the active-cancer evaluation, including the following.
- voiding or renal dysfunction;
- anatomical loss or complete atrophy of a testis;
- surgical scars or painful scars (see scars);
- infertility or impaired fertility;
- endocrine effects such as clinically established hypogonadism;
- peripheral neuropathy, hearing loss or other chemotherapy effects; and
- complications from lymph-node surgery or radiation.
Not every side effect receives a separate rating. A distinct diagnosis, service-connected causal link, and nonoverlapping functional impairment are needed. Section 4.14 prevents paying twice for the same manifestation.
The testicular cancer C&P exam
The record should answer these questions.
- Is the malignancy active, recurrent, metastatic, in remission, or under surveillance?
- What treatment was antineoplastic, and when did it end?
- Has the mandatory six-month post-treatment examination occurred?
- If the cancer is inactive, which voiding or renal residual predominates under DC 7528?
- Was one or both testes removed or completely atrophied?
- Does the record raise SMC for anatomical loss or loss of use of a creative organ?
- What other diagnosed treatment residuals remain, and are they functionally distinct?
- Does the veteran meet a PACT Act or chronic-disease presumptive route?
Why VA denies testicular cancer claims
Testicular cancer claims do slightly better at the Board than the average claim. Across 245 decided Board rulings on testicular cancer from 2021 to 2026, 26.9% were granted, 30.2% denied and 42.9% remanded. That grant rate is 2.2 points above the Board-wide 24.7 percent.
Too few testicular cancer service connection claims were denied for a reliable breakdown of denial reasons. In the denials there were, the Board found no link between the cancer and service. The patterns behind that are predictable.
No route that fits the service. The cancer was diagnosed years after service, the service does not meet the PACT Act location rules, there is no evidence of the disease within the one-year window, and no medical opinion ties it to anything in service.
The wrong presumption. A claim argued only on Agent Orange exposure fails on the presumption, because testicular cancer is not on the § 3.309(e) list. It needs a medical opinion instead.
An opinion built on the diagnosis date. The examiner notes the cancer was diagnosed after service and stops there, without addressing a mass, symptoms or tumor markers recorded during service or the first year after it.
When the Board sends a testicular cancer claim back instead of deciding it, the most common reason is records VA still had to get, followed by an inadequate VA exam or opinion. The Board section below shows the remand reasons and how claims argued as direct and presumptive have fared.
Rating mistakes to watch for
- Treating the six-month date as an automatic reduction rather than the point for a mandatory examination.
- Continuing 100 percent solely because follow-up surveillance continues after antineoplastic treatment has ended.
- Missing recurrence or metastasis evidence that keeps DC 7528 at 100 percent.
- Rating only the orchiectomy and overlooking the active-cancer period.
- Assuming a 0-percent rating for removal of one testis means SMC cannot apply.
- Calling every treatment effect separately compensable without a diagnosis and distinct impairment.
- Ignoring PACT Act eligibility or the one-year malignant-tumor presumption.
Questions veterans ask about testicular cancer
What is the VA rating for testicular cancer?
VA rates testicular cancer at 100 percent under DC 7528 while it is active and during surgery, radiation, chemotherapy or other treatment. The 100 percent continues after treatment ends until a mandatory VA exam six months later. If the cancer has not come back or spread, VA then rates the residuals as voiding or renal dysfunction, whichever is predominant.
How long does the 100 percent rating last after treatment?
It continues until the mandatory VA exam six months after treatment ends, and it does not drop automatically on that date. If the exam shows recurrence or spread, the 100 percent continues. Any reduction has to be proposed in writing with 60 days for you to send evidence under 38 CFR § 3.105(e).
What VA rating do you get for removal of a testicle?
Removal of one testis is 0 percent under DC 7524, and removal of both is 30 percent. If one testis was lost to a service-connected cause and the other is absent or nonfunctioning for an unrelated reason, VA assigns 30 percent. Either way, the loss should be reviewed for special monthly compensation.
Does losing a testicle qualify for SMC(k)?
It can. Under 38 CFR § 3.350(a), the acquired absence of one or both testicles, other than undescended testicles, is loss of a creative organ, which supports special monthly compensation under 38 U.S.C. § 1114(k) when it results from a service-connected disability. An orchiectomy to treat cancer is not an elective operation, so it does not block the benefit.
Is testicular cancer presumptive under the PACT Act?
It can be. The PACT Act presumes reproductive cancer of any type for covered veterans, meaning service on or after August 2, 1990 in listed Gulf War locations or on or after September 11, 2001 in listed post-9/11 locations. Veterans without that service can still use the one-year chronic disease rule or direct evidence.
Is testicular cancer on the Agent Orange list?
No. Testicular cancer is not among the diseases VA presumes from herbicide exposure in 38 CFR § 3.309(e). A Vietnam veteran with testicular cancer needs another route, such as direct evidence with a medical opinion.
Bottom Line
A testicular-cancer claim has two different stages. During active malignancy and qualifying treatment, DC 7528 assigns 100 percent. After treatment and the required examination, VA must determine whether the cancer remains active and, if not, evaluate the proper residuals. The strongest record preserves the oncology timeline, pathology, treatment dates, recurrence status, orchiectomy facts, and every medically identified residual.
Sources and limits
Legal and medical sources: 38 CFR § 4.115b, § 3.307, § 3.309, § 3.350, VA PACT Act benefits, and National Cancer Institute testicular-cancer treatment, checked August 14, 2026. The rating criteria, § 3.105(e), § 3.303(d), the presumptive lists and § 3.350 were checked again against the current eCFR, and 38 U.S.C. §§ 1114(k), 1119 and 1120 against the U.S. Code, on October 6, 2026. Treatment and late effects are from Singla et al., "Testicular Germ Cell Tumors: A Review," JAMA (2025), and Khan et al., "Late side effects of testicular cancer and treatment: a comprehensive review," Discover Oncology (2024), read as PubMed abstracts. Board figures come from Claim Raven's read of 510,968 Board decisions from 2021 to 2026, which contain 1,376,193 rulings; dismissed, withdrawn and moot rulings are excluded from the shares, and the Board section below is computed from the same data. Board results describe appealed cases and do not predict another veteran's outcome.
